{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T05:07:03Z","timestamp":1750309623903,"version":"3.41.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Valproic acid (VPA) has been widely used in Chinese patients after craniotomy. Many studies have focused on the influencing factors of VPA serum concentration, but conclusions are sometimes paradoxical. Furthermore, the concentration of VPA in the cerebrospinal fluid (CSF) has been rarely reported. In the present study, VPA CSF concentrations were measured, and the potential factors influencing serum concentration and CSF distribution of VPA were investigated. In addition, the functional relationship between serum and CSF concentration was explored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Subjects were patients who underwent craniotomy and were administrated with VPA and had a lumbar puncture. Serum and CSF VPA concentrations were measured by use of the Abbott<jats:italic toggle=\"yes\">i1000<\/jats:italic>system.<jats:italic toggle=\"yes\">CYP2C9<\/jats:italic>(430 C&gt;T, 1075 A&gt;C, 1076 T&gt;C, 1080 C&gt;G),<jats:italic toggle=\"yes\">UGT1A6<\/jats:italic>(541 A&gt;G, 552 A&gt;C),<jats:italic toggle=\"yes\">UGT2B7<\/jats:italic>(211 G&gt;T, 802 C&gt;T), and<jats:italic toggle=\"yes\">ABCB1<\/jats:italic>(1236 C&gt;T, 2677 G&gt;T\/A, 3435 C&gt;T) genotypes were determined by direct sequencing. Information, such as age, gender, and height, was collected, and their effect on serum and CSF VPA concentrations was investigated by univariate analysis and multiple linear regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>First, the concomitant use of carbapenems (\u03b2\u2032 = \u22120.422) and<jats:italic toggle=\"yes\">UGT1A6<\/jats:italic>(552 AA \u2192 AC) (\u03b2\u2032 = \u22120.249) had a significant negative correlation with the weight-adjusted VPA serum concentration (C:W ratio), whereas<jats:italic toggle=\"yes\">CYP2C9<\/jats:italic>(1075 AA \u2192 AC) (\u03b2\u2032 = 0.186) and gender (female compared with male) (\u03b2\u2032 = 0.322) showed a positive correlation with VPA serum C:W ratio. The coefficient of determination (<jats:italic toggle=\"yes\">R<\/jats:italic><jats:sup>2<\/jats:sup>) was only 0.348. Second, the relationship between the serum concentration and the CSF square root of the concentration (<jats:italic toggle=\"yes\">R<\/jats:italic><jats:sup>2<\/jats:sup>= 0.705) had a better linear fit. Third, serum VPA concentration (\u03b2\u2032 = 0.810), concomitant use of glycerol fructose (\u03b2\u2032 = 0.160), and age (\u226565 compared with &lt;65) (\u03b2\u2032 = 0.118) showed a positive correlation (<jats:italic toggle=\"yes\">R<\/jats:italic><jats:sup>2<\/jats:sup>= 0.748) with the variability of square root of the concentration of the CSF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>In Chinese patients, after craniotomy, female patients with 1 or more of<jats:italic toggle=\"yes\">CYP2C9<\/jats:italic>(1075 AC) and<jats:italic toggle=\"yes\">UGT1A6<\/jats:italic>(552 AA) genotypes required a lower VPA dosage compared with male patient. There was a better-fitted linear relationship between VPA serum and the square root of CSF concentrations. CSF VPA concentrations were relatively stable, with only age and the use of glycerol fructose having a small influence.<\/jats:p><\/jats:sec>","DOI":"10.1097\/ftd.0000000000000424","type":"journal-article","created":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T17:36:35Z","timestamp":1497029795000},"page":"450-456","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of the Variables Influencing Valproic Acid Concentration in the Serum and Cerebrospinal Fluid of Chinese Patients After Craniotomy"],"prefix":"10.1097","volume":"39","author":[{"given":"Zhihong","family":"Li","sequence":"first","affiliation":[{"name":"Department of Health Statistics, School of Public Health, Shanxi Medical University; and"},{"name":"Department of Pharmacy, Shanxi Da Yi Hospital, Affiliated Da Yi Hospital of Shanxi Medical University, Taiyuan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqi","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanxi Da Yi Hospital, Affiliated Da Yi Hospital of Shanxi Medical University, Taiyuan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guifen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Health Statistics, School of Public Health, Shanxi Medical University; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanxi Da Yi Hospital, Affiliated Da Yi Hospital of Shanxi Medical University, Taiyuan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4046\/trd.2014.77.3.145","article-title":"A case of drug-induced interstitial pneumonitis caused by valproic acid for the treatment of seizure disorders","volume":"77","author":"Kim","year":"2014","journal-title":"Tuberc Respir Dis (Seoul)."},{"key":"R2-20230814","first-page":"193","article-title":"The prevalence of obesity and metabolic syndrome in paediatric patients with epilepsy treated in monotherapy with valproic acid [in Spanish]","volume":"61","author":"Carmona-Vazquez","year":"2015","journal-title":"Rev Neurol."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2515\/therapie\/2010029","article-title":"Therapeutic drug monitoring of valproate [in French]","volume":"65","author":"Bentu\u00e9-Ferrer","year":"2010","journal-title":"Therapie"},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2165\/00003088-200847050-00002","article-title":"Free drug metabolic clearance in elderly people","volume":"47","author":"Butler","year":"2008","journal-title":"Clin Pharmacokinet."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00002512-200320020-00005","article-title":"Drug treatment of epilepsy in elderly people: focus on valproic Acid","volume":"20","author":"Stephen","year":"2003","journal-title":"Drugs Aging."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1177\/0091270009334377","article-title":"Valproic acid plasma concentration decreases in a dose-independent manner following administration of meropenem: a retrospective study","volume":"49","author":"Haroutiunian","year":"2009","journal-title":"J Clin Pharmacol."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/FTD.0000000000000271","article-title":"Effect of UGT2B7 genetic polymorphisms on serum concentrations of valproic acid in Chinese children with epilepsy comedicated with lamotrigine","volume":"38","author":"Wang","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2133\/dmpk.DMPK-11-NT-144","article-title":"Effect of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy","volume":"27","author":"Guo","year":"2012","journal-title":"Drug Metab Pharmacokinet."},{"key":"R9-20230814","article-title":"The risk of hypotension and seizures in patients receiving prophylactic anti-epileptic drugs for supratentorial craniotomy","author":"H\u00f6hne","year":"2016","journal-title":"J Neurosurg Sci."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3171\/2011.4.JNS101585","article-title":"Prophylactic antiepileptic drug therapy in patients undergoing supratentorial meningioma resection: a systematic analysis of efficacy","volume":"115","author":"Komotar","year":"2011","journal-title":"J Neurosurg."},{"key":"R11-20230814","first-page":"1111","article-title":"Comparison of valproate level in human plasma, cerebrospinal fluid and brain tissue following administration of various preparations of valproate and valpromide","volume":"83","author":"Wieser","year":"1994","journal-title":"Praxis (Bern 1994)."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00019052-200304000-00013","article-title":"Mechanisms of antiepileptic drug resistance","volume":"16","author":"Sisodiya","year":"2003","journal-title":"Curr Opin Neurol."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pneurobio.2005.04.006","article-title":"Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases","volume":"76","author":"L\u00f6scher","year":"2005","journal-title":"Prog Neurobiol."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1528-1167.2005.54904.x","article-title":"Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms","volume":"46","author":"Schmidt","year":"2005","journal-title":"Epilepsia"},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/jac\/39.2.295","article-title":"Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem\/betamipron","volume":"39","author":"Nagai","year":"1997","journal-title":"J Antimicrob Chemother."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/jac\/42.4.563","article-title":"Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin","volume":"42","author":"De Turck","year":"1998","journal-title":"J Antimicrob Chemother."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0090-9556(24)15311-1","article-title":"Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats","volume":"27","author":"Yamamura","year":"1999","journal-title":"Drug Metab Dispos."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1023\/A:1013046229699","article-title":"Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits","volume":"18","author":"Yokogawa","year":"2001","journal-title":"Pharm Res."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/FTD.0000000000000316","article-title":"The effect of different carbapenem antibiotics (ertapenem, imipenem\/cilastatin, and meropenem) on serum valproic acid concentration","volume":"38","author":"Wu","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0006-2952(03)00076-5","article-title":"The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases","volume":"65","author":"Ethell","year":"2003","journal-title":"Biochem Pharmacol."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00228-009-0712-x","article-title":"Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling","volume":"65","author":"Jiang","year":"2009","journal-title":"Eur J Clin Pharmacol."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.clineuro.2010.01.002","article-title":"The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients","volume":"112","author":"Tan","year":"2010","journal-title":"Clin Neurol Neurosurg."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00228-016-2087-0","article-title":"Impact of age, gender and CYP2C9\/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid\u2014a large-scale study based on naturalistic therapeutic drug monitoring data","volume":"72","author":"Smith","year":"2016","journal-title":"Eur J Clin Pharmacol."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1124\/jpet.104.081968","article-title":"UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetic: II. Functional impact of the three most common nonsynonymous UTG1A6 polymorphisms (S7A, T181A, and R184S)","volume":"313","author":"Krishnaswamy","year":"2005","journal-title":"J Pharmacol Exp Ther."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/FTD.0000000000000337","article-title":"Effects of UGT1A6 and GABRA1 on standardized valproic acid plasma concentrations and treatment effect in children with epilepsy in China","volume":"38","author":"Feng","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2217\/pgs-2016-0014","article-title":"UGT1A6- and UGT2B7-related valproic acid pharmacogenomics according to age groups and total drug concentration levels","volume":"17","author":"Chatzistefanidis","year":"2016","journal-title":"Pharmacogenomics"},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00228-012-1277-7","article-title":"Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients","volume":"68","author":"Chu","year":"2012","journal-title":"Eur J Clin Pharmacol."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.eplepsyres.2006.04.002","article-title":"The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: a case-matched evaluation based on therapeutic drug monitoring data","volume":"70","author":"Fattore","year":"2006","journal-title":"Epilepsy Res."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2125.1984.tb02401.x","article-title":"Pharmacokinetics of valproic acid in the elderly","volume":"17","author":"Perucca","year":"1984","journal-title":"Br J Clin Pharmacol."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10928-013-9323-3","article-title":"Sex related differences on valproic acid pharmacokinetics after oral single dose","volume":"40","author":"Ibarra","year":"2013","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0278-5846(82)80172-3","article-title":"Sodium valproate: kinetic profile and effects on GABA levels in various brain areas of the rat","volume":"6","author":"Mesdjian","year":"1982","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/jpet.106.102491","article-title":"Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays","volume":"320","author":"Baltes","year":"2007","journal-title":"J Pharmacol Exp Ther."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.addr.2004.07.011","article-title":"Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics","volume":"56","author":"Shen","year":"2004","journal-title":"Adv Drug Deliv Rev."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy","volume":"16","author":"L\u00f6scher","year":"2002","journal-title":"CNS Drugs."},{"key":"R35-20230814","first-page":"256","article-title":"Distribution of valproate to subdural cerebrospinal fluid, subcutaneous extracellular fluid, and plasma in humans: a microdialysis study","volume":"42","author":"Lindberger","year":"2001","journal-title":"Epilepsia"},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2125.1983.tb02179.x","article-title":"Plasma protein-binding and CSF concentrations of valproic acid in man following acute oral dosing","volume":"16","author":"Rapeport","year":"1983","journal-title":"Br J Clin Pharmacol."},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/clpt.1985.116","article-title":"Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults","volume":"37","author":"Bauer","year":"1985","journal-title":"Clin Pharmacol Ther."},{"key":"R38-20230814","first-page":"789","article-title":"The blood-brain barrier: implications for chemotherapy in brain tumors","volume":"39","author":"Boaziz","year":"1991","journal-title":"Pathol Biol (Paris)."},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1152\/ajplegacy.1970.219.1.270","article-title":"Effect of concentrated solutions on blood-brain barrier","volume":"219","author":"Rapoport","year":"1970","journal-title":"Am J Physiol."},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1023\/A:1007049806660","article-title":"Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications","volume":"20","author":"Rapoport","year":"2000","journal-title":"Cell Mol Neurobiol."},{"key":"R41-20230814","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2174\/138161282005140214165212","article-title":"ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development","volume":"20","author":"Choi","year":"2014","journal-title":"Curr Pharm Des."},{"key":"R42-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","article-title":"The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade","volume":"18","author":"Kathawala","year":"2015","journal-title":"Drug Resist Updat."},{"key":"R43-20230814","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1602\/neurorx.2.1.86","article-title":"Blood-brain barrier active efflux transporters: ATP-binding cassette gene family","volume":"2","author":"L\u00f6scher","year":"2005","journal-title":"NeuroRx"},{"key":"R44-20230814","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1474-4422(13)70128-5","article-title":"P-glycoprotein expression and antiepileptic drug resistance","volume":"12","author":"French","year":"2013","journal-title":"Lancet Neurol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201708000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T02:54:07Z","timestamp":1750301647000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201708000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000424","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}